Ophorst O - Search Results

1

The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella.

van der Put RMF, Smitsman C, de Haan A, Hamzink M, Timmermans H, Uittenbogaard J, Westdijk J, Stork M, Ophorst O, Thouron F, Guerreiro C, Sansonetti PJ, Phalipon A, Mulard LA. van der Put RMF, et al. Among authors: ophorst o. ACS Cent Sci. 2022 Apr 27;8(4):449-460. doi: 10.1021/acscentsci.1c01479. Epub 2022 Mar 17. ACS Cent Sci. 2022. PMID: 35559427 Free PMC article.

2

Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.

Donadei A, Kraan H, Ophorst O, Flynn O, O'Mahony C, Soema PC, Moore AC. Donadei A, et al. Among authors: ophorst o. J Control Release. 2019 Oct;311-312:96-103. doi: 10.1016/j.jconrel.2019.08.039. Epub 2019 Sep 1. J Control Release. 2019. PMID: 31484041

3

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M. Ophorst OJ, et al. Infect Immun. 2006 Jan;74(1):313-20. doi: 10.1128/IAI.74.1.313-320.2006. Infect Immun. 2006. PMID: 16368986 Free PMC article.

4

Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence.

Ophorst OJ, Radosević K, Ouwehand K, van Beem W, Mintardjo R, Sijtsma J, Kaspers J, Companjen A, Holterman L, Goudsmit J, Havenga MJ. Ophorst OJ, et al. Vaccine. 2007 Feb 9;25(8):1426-36. doi: 10.1016/j.vaccine.2006.10.050. Epub 2006 Nov 7. Vaccine. 2007. PMID: 17161889

5

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.

Ophorst OJ, Radosević K, Klap JM, Sijtsma J, Gillissen G, Mintardjo R, van Ooij MJ, Holterman L, Companjen A, Goudsmit J, Havenga MJ. Ophorst OJ, et al. Vaccine. 2007 Aug 29;25(35):6501-10. doi: 10.1016/j.vaccine.2007.06.019. Epub 2007 Jun 29. Vaccine. 2007. PMID: 17646036

6

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.

Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yüksel S, Osterhaus AD, Havenga MJ. Ophorst OJ, et al. Vaccine. 2004 Aug 13;22(23-24):3035-44. doi: 10.1016/j.vaccine.2004.02.011. Vaccine. 2004. PMID: 15297053

7

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. Vogels R, et al. Among authors: ophorst o. J Virol. 2003 Aug;77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003. J Virol. 2003. PMID: 12857895 Free PMC article.

8

Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A. Havenga MJ, et al. Among authors: ophorst oj. J Virol. 2002 May;76(9):4612-20. doi: 10.1128/jvi.76.9.4612-4620.2002. J Virol. 2002. PMID: 11932426 Free PMC article.

9

Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.

Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, Gillissen G, Hoeben RC, ter Horst M, Nanda D, Dirven C, Avezaat CJ, Goudsmit J, Sillevis Smitt P. Brouwer E, et al. Among authors: ophorst o. Cancer Gene Ther. 2007 Feb;14(2):211-9. doi: 10.1038/sj.cgt.7701010. Epub 2006 Nov 3. Cancer Gene Ther. 2007. PMID: 17082793

10

Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells.

de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Lougheed SM, Radosevic K, Havenga MJ, Scheper RJ. de Gruijl TD, et al. Among authors: ophorst oj. J Immunol. 2006 Aug 15;177(4):2208-15. doi: 10.4049/jimmunol.177.4.2208. J Immunol. 2006. PMID: 16887980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page